Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SQUIBB's CAPOTEN FIRST QUARTER WORLDWIDE SALES INCREASE 80%

Executive Summary

SQUIBB's CAPOTEN FIRST QUARTER WORLDWIDE SALES INCREASE 80% over 1983 first quarter results, the company said in a recent financial report. "In the major markets of Europe where it is now indicated for broad use in hypertension, Capoten's first quarter sales were double those of last year," the firm noted. Squibb President Richard Furland indicated that the company expects that FDA may "soon" approve Capoten for mild to moderate hypertension. Furlaud added that Corgard sales "increased satisfactorily during the quarter while sales of insulin products and psychotropics continued to be strong." Sales of Squibb's pharmaceutical products group were up 2% to $238.2 mil. for the quarter, the firm said. Overall, Squibb's first quarter sales gained 6.1% to $428.9 mil., accompanied by a 10.8% increase in net income to $36.9 mil. The firm's overall sales growth received a boost from the firm's medical products group, which turned in a 10% sales gain to $95.5 mil. despite the current cautious atmosphere in the hospital market [EDITORS' NOTE: See table on p. 18 for other firms reporting sales & earnings]. Also reporting first quarter financial results, SmithKline Beckman said that its "main strength" in ethical pharmaceuticals was in "U.S. cardiovascular products, primarily Dyazide." SmithKline Beckman President Henry Wendt noted that "U.S. and internatl. sales of Tagamet also were up, but only modestly, reflecting the competition in the ulcer market." For the first quarter, SmithKline reported a 5.7% increase in sales to $718.7 mil. with earnings (not including a $3.3 mil. gain from the sale of the firm's industrial business) edging upward 3.7% to $130.5 mil. "Strong overall performance by our therapeutics group, combined with some firming in our diagnostic/analytical group, enabled us to move ahead despite competitive pressures and the continued negative impact of the strong U.S. dollar on internatl. results," Wendt said. Negative currency transaction hurt total corporate sales by $21 mil. in the quarter, he noted.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel